Variable | OR | 95% CI | p |
---|---|---|---|
MODEL 1 | |||
AKI | 4.66 | 1.94–11.17 | < 0.001 |
Cancer | 3.94 | 1.74–8.89 | < 0.001 |
Length of stay in hospital | 1.07 | 1.03–1.10 | < 0.001 |
Leukocytes | 1.08 | 1.01–1.15 | 0.016 |
Diabetes | 0.31 | 0.11–0.80 | 0.016 |
MAP | 0.98 | 0.96–1.00 | 0.126 |
Age | 1.02 | 0.98–1.05 | 0.195 |
MELD | 1.04 | 0.97–1.11 | 0.247 |
APACHE II | 0.97 | 0.88–1.05 | 0.427 |
Suspected infection | 0.76 | 0.35–1.63 | 0.483 |
Baseline eGFR | 1.07 | 0.77–1.47 | 0.694 |
Male Sex | 1.16 | 0.51–2.59 | 0.726 |
Hypertension | 0.89 | 0.37–2.09 | 0.788 |
Urea | 0.99 | 0.98–1.01 | 0.868 |
MODEL 2 | |||
Progression of AKI | 12.05 | 3.29–44.07 | < 0.001 |
Cancer | 10.27 | 2.73–38.47 | < 0.001 |
Age | 1.08 | 1.02–1.14 | 0.006 |
MELD | 1.15 | 1.03–1.26 | 0.006 |
Length of stay in hospital | 1.08 | 1,02 - 1,13 | 0.007 |
Urea | 1.01 | 0.99–1.02 | 0.073 |
MAP | 0.98 | 0.95–1.00 | 0.090 |
APACHE II | 0.93 | 0.82–1.05 | 0.240 |
Baseline eGFR | 0.81 | 0.55–1.17 | 0.273 |
Hypertension | 0.53 | 0.14–1.87 | 0.322 |
Leukocytes | 1.04 | 0.95–1.13 | 0.367 |
Male Sex | 1.26 | 0.38–4.10 | 0.702 |
Diabetes | 0.89 | 0.26–2.99 | 0.852 |
Suspected infection | 1.09 | 0.34–3.46 | 0.882 |